Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lei Sun
Observed name:
Lei Sun, PhD
Institution:
Alkermes (United States)
Observed institution:
Alkermes (United States)
ORCID:
0000-0003-1669-1718
Observed ORCID:
0000-0003-1669-1718
OpenAlex ID:
A5073779984
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies
2022
·
Borje Darpo
, Marie Borin
, et al.
·
The Journal of Clinical Pharmacology
·
15
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
2021
·
Omid Hamid
, Stephen V. Liu
, et al.
·
Journal of Clinical Oncology
·
11
Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1 (077)
2022
·
Ira Winer
, Ulka Vaishampayan
, et al.
·
Gynecologic Oncology
·
10
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326)
2022
·
Thomas Herzog
, Kathleen Moore
, et al.
·
Gynecologic Oncology
·
1
Show more works
View as search
Works count:
4
Citation count:
37
H-index:
3
I10-index:
3
Year
Topic
Type